Mylan CEO Heather Bresch said they are actively addressing, shortages of the vital drug resulting from manufacturing issues that other suppliers have experienced.
"Mylan has already ramped up its production in order to try to meet the increased demand," Bresch added.
"Mylan is aggressively working on both the manufacturing and regulatory fronts to expedite the FDA regulatory approvals necessary to further increase capacity."